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ABSTRACT 
Objective: Diabetes mellitus is a serious, complex metabolic disorder and growing health threat disease in the world. Berberine, one of the main 
constituent in Rhizoma coptidis is widely used in the treatment of diabetes. Potential of berberine in the management of diabetic complications, 
namely diabetic nephropathy and cardiomyopathy, is however, not yet explored. The present study was, therefore, undertaken to explore the 
potential of berberine for the management of diabetic nephropathy and diabetic cardiomyopathy in high-fat diet (HFD) and low dose streptozotocin 
(STZ) induced diabetes in rats.  
Methods: Rats were fed a high-fat diet for 4 w followed by a single intraperitoneal dose of streptozotocin (35 mg/kg). Animals were divided in five 
groups. Berberine was given orally in two different dose levels (75 mg/kg and 150 mg/kg) for 28 d. Metformin (100 mg/kg) was used as a standard 
antidiabetic drug. At the end of the study, parameters evaluated includes glycemic profile, lipid profile, left ventricular indices, urinary protein, 
serum creatinine, blood urea nitrogen and cardiac antioxidants. Histopathology of kidney and pancreas was carried out.  
Results: Berberine treated groups showed a significant decrease in fasting blood glucose, glycosylated Hb, creatinine, blood urea nitrogen and urinary 
total proteins, whereas there was a significant improvement in serum insulin, liver glycogen, skeletal muscle glycogen and cardiac antioxidant enzymes.  
Conclusion: Present study indicated that berberine shows a protective role in diabetes-associated renal and cardiovascular complications. 
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INTRODUCTION 
Diabetes mellitus is one of the metabolic disorders characterized by 
abnormally high levels of blood glucose. It has been recognized as a 
growing worldwide epidemic by the World Health Organisation 
(WHO). Diabetes has become the disease of concern, particularly for 
Indians as India is now considered as the capital of diabetes patients, 
with 62.4 million Indians having type II diabetes mellitus [1].  
In type II diabetes mellitus, progressive decline in insulin action 
referred as insulin resistance and pancreatic β-cell dysfunction leads 
to increased levels of blood glucose [2]. A major risk factor for 
insulin resistance is obesity, which is generally caused by a western-
style high fatty diet and physical inactivity [3]. The development of 
insulin resistance in obesity exhibits accelerated lipolytic activity 
with increased release of free fatty acids (FFA) into the portal 
circulation. The FFA may be cytotoxic by inducing lipid peroxidation 
and hepatocyte apoptosis resulting in fatty liver disease. Further, 
studies have shown that both obesity and type II diabetes impair 
insulin-induced suppression of glycogenolysis and gluconeogenesis. 
The current treatment for type II diabetes includes insulin and oral 
hypoglycemic drugs such as biguanides, sulfonylurea derivatives, 
thiazolidinediones and α-glucosidase inhibitors. These medications 
have side effects, e. g. thiazolidinediones induce obesity, 
osteoporosis and sodium retention; sulfonylurea derivatives can 
lead to incidences of severe hypoglycemia, whereas biguanides like 
metformin put patients at risk of developing lactic acidosis [4]. 
Further, the oral monotherapy with lifestyle changes is not sufficient 
for most of the diabetic patients and requires various oral 
combinations or addition of insulin [5]. Thus, there is an increasing 
need to search for effective antidiabetic agents exhibiting fewer side 
effects. As an alternative, large number of population is trying to rely 
on plant-based remedies for management of this metabolic disorder. 
Berberine is a natural alkaloid which is present in Hydrastis 
canadensis (goldenseal), Berberis vulgaris (barberry), Berberis 
aquifolium (Oregon grape), Coptis chinensis (Coptis or golden thread) 
and Berberis aristata (tree turmeric). Berberine is reported to be 
useful in the Indian traditional system since a long time for various 
ailments, including diabetes, hyperlipidemia, oxidative stress, cancer 
and inflammation [6-9]. Berberine is reported to exhibit antidiabetic 
activity through promoting regeneration and functional recovery of 
β-cells as well as by improvement of insulin sensitivity [10, 11]. 
Considering the role of berberine as an insulin sensitizer, we have 
undertaken the present study with an objective to evaluate the effect 
of berberine on diabetic nephropathy and cardiomyopathy in HFD-
low dose STZ induced type II diabetes in rats. 
MATERIALS AND METHODS 
Drugs and chemicals 
Berberine was purchased from TCI Chemicals (India) Pvt Ltd. 
Streprozotocin (STZ) was purchased from Sigma chemicals, Germany. 
Kits for estimation of total cholesterol (TC), triglyceride (TG), high-
density lipoprotein (HDL), creatinine, blood urea nitrogen (BUN), total 
proteins, SGOT, SGPT and ALP were purchased from Erba diagnostics. 
All other chemicals used in study were of high-quality analytical grade. 
Experimental animals 
Healthy male Sprague Dawley rats (150-180 g) were procured from 
National Institute of Bioscience, Chaturshrungi, Pune. Animals were 
housed in a group of 6 per cage in standard polypropylene cages 
lined with raw husk. The animal house was maintained on 12 h 
light/dark cycle at approximately 22±2 C, relative humidity 60-
70%. After randomization into various groups and before initiation 
of the experiment, the rats were acclimatized for a period of 7 d. 
Before and during the experiment rats were fed with standard 
laboratory diet (Nutrivet Lifescience, Pune, Maharashtra) and water 
ad libitum. All experimental procedures were carried out in 
accordance to Institutional Animal Ethics Committee (IAEC) as per 
the CPCSEA guidelines (Approval No-MCP/IAEC/009/2017). 
International Journal of Pharmacy and Pharmaceutical Sciences 
Print ISSN: 2656-0097 | Online ISSN: 0975-1491                            Vol 12, Issue 8, 2020 
Bandawane et al. 
Int J Pharm Pharm Sci, Vol 12, Issue 8, 41-48 
42 
 
Induction of diabetes mellitus 
Rats were given a high-fat diet (58% fat, 25% protein and 17% 
carbohydrate, as a percentage of total kcal), the composition of 
which was slightly modified as per documented by Srinivasan K 
[12]. After 4 w, rats were injected STZ (35 mg/kg, i. p.) prepared 
freshly in cold citrate buffer (pH 4.5). Seven d after STZ injection, 
rats showing fasting blood glucose level more than 200 mg/dl were 
considered diabetic. 
Experimental design 
Animals were divided into five groups, each consisting of six rats as 
follows. 
Group I: Normal control rats, administered saline (0.9% w/v) for 28 d 
Group II: Diabetic control rats received HFD for 4 w followed by a 
single intraperitoneal dose of STZ (35 mg/kg) 
Group III: Diabetic rats received metformin (100 mg/kg) for 28 d 
Group IV: Diabetic rats received berberine (75 mg/kg) for 28 d 
Group V: Diabetic rats received berberine (150 mg/kg) for 28 d  
At the end of the study period, rats were fasted overnight, sacrificed 
and serum separated from collected blood samples for various 
biochemical estimations. 
Measurement of physical parameters 
During the treatment period, body weight, food intake and water 
intake of rats were recorded and the change in these parameters 
was calculated. Basal metabolic index (BMI) calculated as per 
formula [13].  




Evaluation of antihyperglycemic parameters 
Blood glucose estimation 
Fasting blood glucose level was determined in all experimental rats 
initially to determine the diabetic status and thereafter every week 
during the 28 d study period.  
Oral glucose tolerance test (OGTT) 
OGTT was performed in overnight fasted (18 h) rats at the end of 
28th d of the study period. All experimental groups were fed with 
glucose (4 g/kg) 30 min after the administration of drugs. Blood 
glucose was determined at 0, 30, 60, 90 and 120 min of glucose 
administration [14]. 
Estimation of biochemical parameters 
At the end of 28 d, blood was subjected for determination of 
glycosylated hemoglobin and serum for the determination of insulin. 
Liver and skeletal muscles of individual rats were homogenised in 
5% w/v trichloroacetic acid and its glycogen content was 
determined by the method of Carrol [15].  
Evaluation of diabetic cardiomyopathy 
Lipid profile 
At the end of 28 d, blood was collected from inferior vena cava, 
serum separated and subjected for determination of parameters like 
total cholesterol (T-CH), high-density lipoproteins (HDL-CH) and 
triglycerides (TG) using commercially available kits. Very low-
density lipoproteins (VLDL-CH) and low-density lipoproteins (LDL-
CH) were calculated using the Friedewald’s formula [16, 17]. 
Atherogenic index (AI) and coronary risk index (CRI) were 
calculated as an indicator for atherosclerotic lesion and coronary 
atherosclerosis development, respectively [18, 19]. 
Cardiac and left ventricular hypertrophic indices 
At the end of the experiment, the heart was blotted with filter paper 
to remove an excess of water. Extraneous tissues from the heart 
were removed and the weight of the heart was noted. Index of 
hypertrophy was calculated as the ratio of heart weight to body 
weight (HW/BW) using the following formula [20].  




Left ventricle of the heart was isolated and weighed. Left 
ventricular hypertrophy index was calculated using the 
following formula:  
Left ventricular hypertrophy index =  
Left ventricular weight (mg)
Bodyweight (g)
 
Evaluation of cardiac anti-oxidant activity 
Estimation of superoxide dismutase (SOD) 
The SOD activity was measured according to the method of 
Marklund [21]. 
Estimation of catalase (CAT) 
Catalase was measured according to the method described by 
Sahreen et al. [22].  
Estimation of MDA lipid peroxidation 
MDA lipid peroxidation was estimated according to the method 
described by Kumar et al. [23]. 
Evaluation of diabetic nephropathy 
The 24 h urine sample collected from each rat was centrifuged. 
Urinary total protein, as well as plasma uric acid, plasma urea, serum 
creatinine and blood urea nitrogen, were determined using 
commercial kits. Kidney hypertrophy index was estimated as per the 
following formula [12]. 
Kidney hypertrophy index =  
Kidney weight (g) × 100
Bodyweight (g)
 
Histopathological studies  
Pancreas and kidney samples of rats were isolated and fixed in 10% 
neutral buffer formalin, rinsed by xylene and embedded in paraffin. 
Tissue sections (5 µm thickness) were cut and stained with 
hematoxylin-eosin (HE) dye for histopathological examination using 
light microscopy [24].  
Statistical analysis 
All results were expressed as the mean±SEM. p-value of<0.05 
was considered statistically significant. The data was analysed 
for statistical significance by one-way analysis of variance 
(ANOVA) followed by Dunnet’s multiple test for comparison. 
GraphPad Instat version 3 was the statistical software used for 
analysis. 
RESULTS 
Effect on parameters of the antihyperglycemic study 
Effect of berberine on blood glucose level in diabetic rats is 
shown in fig. 1. A sustained and significant (p<0.001) decrease in 
blood glucose level was observed in dose dependent manner in 
berberine treated groups during 28 d period as compared to 
diabetic control. 
Table 1 depicts the effect of a single oral administration of berberine 
on glucose tolerance, which exhibited a maximum fall in 
postprandial glucose level at 30 min. 
As shown in table 2, oral administration of berberine significantly 
restored the levels of glycosylated haemoglobin (p<0.001) and 
serum insulin (p<0.01) in diabetic rats. Oral administration of 
berberine for 28 d significantly (p<0.001) restored the decreased 
glycogen content in liver and skeletal muscles in diabetic rats. 
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Fig. 1: Effect of oral administration of berberine on fasting blood glucose level, Values are expressed as mean±SEM ##p value<0.01, ###p 
value<0.001 as compared to NC, *p value<0.05, **p value<0.01, ***p value<0.001 as compared to DC 
 
Table 1: Effect of berberine (BBR) on oral glucose tolerance test 
Experimental groups Blood glucose (mg/dl) 
0 min 30 min 60 min 90 min 120 min 
Normal Control (NC) 85.5±3.50 109.3±3.34 102±5.15 99.83±4.5 95.5±4.4 
Diabetic Control (DC) 469.8±11.6## 544.8±6.5### 560±4.3### 530.7±5.51### 514.16±6.4### 
DC+MET (100 mg/kg) 141.5±3.9 157.5±5.1** 157.7±4.6** 135.7±4.8*** 119.5±2.95*** 
DC+BBR (75 mg/kg) 163.5±2.54 204.5±3.8ns 192.3±4.7* 172.8±6.24* 151±4.6** 
DC+BBR (150 mg/kg) 159.3±7.6 181.2±4.06* 168.5±4.4** 151.0±4.6** 130±3.22*** 
Values are expressed as mean±SEM ##p value<0.01, ###p value<0.001 as compared to NC, *p value<0.05, **p value<0.01, ***p value<0.001 as 
compared to DC 
 
Table 2: Effect of berberine (BBR) on biochemical parameters 










Glycosylated haemoglobin (%) 6.38±0.25 9.3±0.27### 6.8±0.22*** 7.41±0.2** 6.93±0.2*** 
Serum insulin (μIU/ml) 10.09±0.52 3.51±0.3### 6.47±0.21*** 5.25±0.23* 6.02±0.19** 
Glycogen content in skeletal 
muscles (mg/100) 
48±1.8 9.8±1## 41.7±1.2*** 35.7±1.3*** 39.3±0.9*** 
Glycogen content in liver 
(mg/100) 
24.83±1.9 9.7±1.2### 23.17±2*** 16.33±1.9* 21.7±1.9*** 
Values are expressed as mean±SEM ##p value<0.01, ###p value<0.001 as compared to NC, *p value<0.05, **p value<0.01, ***p value<0.001 as 
compared to DC 
 
Effect on parameters of diabetic cardiomyopathy 
As shown in fig. 2, diabetic rats treated with berberine showed a 
significant reduction in the elevated levels of total cholesterol 
(p<0.01), triglyceride (p<0.001), LDL-CH (p<0.01) and VLDL-CH 
(p<0.05) in diabetic rats. On the contrary, there was significant 
(p<0.01) improvement in HDL-CH level in BBR treated groups as 
compared to diabetic control. 
 
 
Fig. 2: Effect of berberine (BBR) on lipid profile, values are expressed as mean±SEM ##p value<0.01, ###p value<0.001 as compared to NC, 
*p value<0.05, **p value<0.01, ***p value<0.001 as compared to DC 
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As shown in table 3, there was a significant increase in myocardial 
MDA, whereas a decrease in SOD and CAT levels in diabetic control 
rats. Berberine treatment exhibited significant (p<0.01) reduction in 
myocardial MDA with a significant increase in SOD (p<0.001) and 
CAT (p<0.01) levels of myocardium in treatment groups compared 
to diabetic control rats. There was a significant reduction in cardiac 
hypertrophy index (p<0.001), left ventricular hypertrophy index 
(p<0.01) and heart weight (p<0.001) after berberine treatment. As 
shown in table 3, berberine at dose of 150 mg/kg showed significant 
(p<0.001) reduction in atherogenic and coronary risk indices. 
 
Table 3: Effect of berberine (BBR) on cardiac parameters 










SOD (U/mg of protein) 12.66±0.57 3.86±0.5### 11.64±0.8*** 8.82±0.6** 10.71±0.5*** 
CAT (µmoles of H2O2 
utilized/min/mg/protein) 
77.90±4.64 34.17±2.2### 60.38±3.6*** 51.84±3.04* 51.52±2.5** 
MDA (µmol/gram) 200.42±4.6 396.2±20.8### 206.6±5.9*** 227.5±7.61* 216.44±3.5** 
Cardiac hypertrophy (mg/gram) 7.918±0.14 6.35±0.17## 6.2±0.19*** 5.83±0.12** 6.05±0.2*** 
Left Ventricular hypertrophy 
(mg/gram) 
0.65±0.01 0.7±0.013## 0.64±0.01*** 0.72±0.008 0.69±0.009** 
Atherogenic risk index 0.78±0.06 9.6±2.76### 1.7±0.41*** 2.48±0.7** 1.8±0.34*** 
Cardiac risk index 1.78±0.03 10.6±2.8### 2.7±0.41*** 3.48±0.7** 2.7±0.32*** 
Heart weight (mg) 1.25±0.94 1.7±0.03### 1.2±0.01*** 1.26±0.01** 1.2±0.01*** 
Values are expressed as mean±SEM ##p value<0.01, ###p value<0.001 as compared to NC, *p value<0.05, **p value<0.01, ***p value<0.001 as 
compared to DC 
 
Effect on parameters of diabetic nephropathy 
As shown in the table 4, there was a significant increase (p<0.01) 
in serum urea, serum creatinine and blood urea nitrogen in 
diabetic control rats. Berberine treatment exhibited significant 
(p<0.01) reduction in these renal parameters as compared to 
diabetic control rats. The urine volume (24 h) of diabetic rats 
was found to be significantly increased as compared to the 
normal control group. After 28 d of treatment with berberine, 
urine volume significantly (p<0.01) reduced as compared to 
diabetic control.  
Effect on physical parameters  
Table 5 shows that the bodyweight of diabetic rats was significantly 
(p<0.001) increased as compared to the normal rats throughout the 
experimental period. After treatment with berberine, the bodyweight 
significantly (p<0.05) reduced as compared to diabetic control groups. 
Moreover, diabetic rats showed a significant increase (p<0.001) in 
food intake as compared with the normal group. Oral administration of 
berberine for 28 d significantly (p<0.01) reduced food intake as 
compared to diabetic control. At the end of the study period, a 
significant decrease (p<0.01) in the water intake was observed in 
berberine treated groups as compared to diabetic control. 
 
Table 4: Effect of berberine (BBR) on renal parameters 










Urinary protein (mg/dl) 6.38±0.25 9.26±0.27### 6.75±0.22*** 7.41±0.20** 6.93±0.21*** 
Serum creatinine (mg/dl) 0.348±0.02 0.94±0.043## 0.4±0.02*** 0.53±0.265* 0.49±0.014** 
BUN (mg/dl) 66.37±2.6 185.4±4.75## 110.5±2.9*** 136.5±3.11* 122.1±2.29** 
Serum Uric acid (mg/dl) 1.3±0.21 2.28±0.12# 1.42±0.20**  1.96±0.11ns 1.49±0.16* 
Serum Urea (mg/dl) 23.4±1.3 52.32±2.0## 25.13±2.05*** 36.5±2.43* 29.98±1.26** 
KW/BW ratio 2.93±0.07 7.18±0.08### 3.92±0.09*** 4.91±0.08** 4.36±0.09*** 
Values are expressed as mean±SEM #p value<0.05, ##p value<0.01, ###p value<0.001 as compared to NC, *p value<0.05, **p value<0.01, ***p 
value<0.001 as compared to DC 
 
Table 5: Effect of berberine (BBR) on body weight, feed intake, water intake and urine volume 
Experimental  
groups 
Bodyweight (g)  Feed intake (g) Water intake (ml) Urine volume (ml) 
Initial Final Initial Final Initial  Final Initial Final 
Normal control 
(NC) 












16.5±1.4*** 42.0±2.6ns 26.67±2.80*** 13.83±1.6** 13.33±1.6*** 
DC+BBR  
(75 mg/kg) 
211.8±3.6ns 215.8±2.82** 22.16±1.7ns 20.83±1.19** 47.5±2.4ns 28.33±2.04** 18.33±7.5* 15.33±1.8** 
DC+BBR 
(150 mg/kg) 
236.8±4.3ns 199.5±5.6*** 24.33±2.18ns 16.67±1.5*** 12.33±1.14ns 23.33±2.10** 16.16±1.24ns 13.5±2.1** 
Values are expressed as mean±SEM ##p value<0.01, ###p value<0.001 as compared to NC, *p value<0.05, **p value<0.01, ***p value<0.001 as 
compared to DC 
 
Effect of berberine on histopathology of the pancreas is shown in fig. 
3. Diabetic rat pancreas shows necrosis of pancreatic islets and 
surrounding acini. Treatment with berberine for 28 d exhibited 
dose-dependent improvement in the pancreas histology. 
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Fig. 3: (a-e) Effect of berberine on histology of pancreas in different experimental groups, (a) Normal histological structure of rat 
pancreas showing normal histology, (b) Diabetic rat pancreas shows necrosis of Islets of Langerhans (arrow) and surrounding acini of 
exocrine pancreas (arrowhead), (c) Diabetic rats treated with metformin (100 mg/kg) show is normal histology, acinus (arrowhead), 
interlobular duct (large arrow), intercalated duct (small arrow), Islet of Langerhans (star), (d) Oral administration of 75 mg/kg of BBR in 
diabetic rats show slight changes in pancreas, (e) treatment with 150 mg/kg of BBR significantly improved in the histological structure of 
pancreas. Photomicrographs are taken under 400X magnification 
 
Fig. 4 shows effect of berberine on histopathology of kidney. Diabetic 
rat kidney shows cytoplasmic vacuolation of tubules, tubular dilation 
and lymphocytic infiltration. Treatment with berberine for 28 d 
exhibited dose-dependent improvement in the kidney histology. 
 
 
Fig. 4: (a-e) Effect of berberine on histology of pancreas in different experimental groups. (a) Normal histological structure of kidney 
showing the normal histological structure, (b) Diabetic rat kidney showing cytoplasmic vacuolation of tubules, tubular dilation and 
lymphocytic infiltration, (c) Diabetic rats treated with metformin (100 mg/kg) (d) Oral administration of 75 mg/kg of berberine for 28 d 
in diabetic rats show slight changes in glomerulus and tubules; (e) Treatment with 150 mg/kg berberine shows improvement in 
histological structure of glomerulus. Photomicrographs are taken under 400X magnification 
 
DISCUSSION 
Diabetes mellitus is a common endocrine disorder characterized by 
chronic hyperglycemia due to either insufficient insulin production 
by pancreatic beta cells or by cellular resistance to insulin [25]. 
According to IDF, one-third of our elderly population suffers from 
diabetes mellitus [26]. Importantly, patients with type II diabetes 
mellitus display higher risk to develop severe complications such as 
cardiomyopathy, nephropathy, neuropathy and retinopathy [27-30].  
In the present study, the effect of berberine (BBR) on diabetic 
complications like nephropathy and cardiomyopathy were assessed 
using a high-fat diet (HFD) and low dose streptozotocin (STZ) 
induced diabetic rat model. STZ has been known to mediate 
pancreatic β-cell toxicity by generating reactive oxygen species [31]. 
HFD on the other hand is known to increase visceral fat depots by 
altering the carbohydrate and lipid metabolism, thereby leading to 
insulin resistance [32]. This model of HFD-low dose STZ induced 
diabetes thus mimics the condition of insulin resistance observed 
currently in the society because of a sedentary lifestyle and 
modernized dietary habits. 
In this present study, the administration of STZ-HFD for 4 w induced 
type II diabetes mellitus in the experimental animals as indicated by 
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rise in fasting blood glucose and is in accordance with earlier studies 
reported [33]. Postprandial blood glucose level plays an important 
role in diabetes-associated complications. Hence we carried out 
fasting blood glucose level and oral glucose tolerance test. 
In the present study significant increase in fasting and postprandial 
blood glucose level observed in HFD-STZ induced diabetic animals 
indicates various possibilities including injury to pancreatic beta 
cells or reduced peripheral utilization of blood glucose by the target 
tissues or increased production of glucose by liver cells or increased 
breakdown of glycogen in the liver [34-36]. Decrease in the blood 
glucose levels as observed in BBR treated groups indicates the role 
of BBR in improving glycemic control either through pancreatic cells 
regeneration or by improving the peripheral utilization of glucose as 
in accordance with earlier studies [37]. Measurement of serum 
insulin is an important aspect for antidiabetic research as it provides 
an idea of whether the drug improves the condition of damaged beta 
cells of pancreas or not [38]. In the present study, improvement in 
serum insulin in BBR treated groups as compared to diabetic control 
rats indicates that BBR either regenerate pancreatic beta cells or 
may improve insulin secretion from residual β-cell of the pancreas. 
The claim is further strengthened from the histopathological study 
of pancreas, which showed improved histology of pancreas in drug-
treated experimental groups. 
Persistent rise in blood glucose level results in long term diabetic 
complications mainly because of the formation of glycosylated 
haemoglobin (HbA1c), which further damages the blood vessels 
through oxidative stress [39-40]. In the present study, oral 
administration of BBR significantly decreased in HbA1c levels, 
possibly by preventing oxidative damage caused by glycation 
reaction in diabetic conditions as a result of decreased blood glucose 
level and increased insulin secretion.  
The antihyperglycemic effect of BBR could be connected to its ability 
to increase insulin secretion and glucose storage as glycogen in the 
liver and skeletal muscles of HFD and STZ induced type II diabetic 
rats. In addition, glycogen may be considered a reliable marker for 
assessing the antihyperglycemic potential of any drug. Generally, 
decreased glycogen synthesis, increased glycogenolysis and 
increased hepatic glucose production are the major symptoms in 
type II diabetes.  
In the study, the increased liver glycogen and skeletal glycogen 
content after treatment with berberine could be attributed to an 
amelioration of the glycogenolytic and gluconeogenic pathway 
secondary to the increase of insulin level in the blood.  
Earlier studies have shown that in STZ-HFD diabetic rats, 
hyperglycemia is associated with hypercholesterolemia and 
hypertriglyceridemia, which play a key role in the pathogenesis of 
diabetic cardiomyopathy. Moreover, the rate of free fatty acid uptake 
by myocardium is inversely proportional to the severity of the 
myocardial dysfunction [15]. Dyslipidaemia has been the major 
predictor of cardiaovascular adverse events in diabetic patients [41]. 
Elevated total cholesterol (T-CH), triglycerides (TG), low-density 
lipoproteins (LDL-CH), very low-density lipoproteins (VLDL-CH) 
levels in diabetic rats was reduced and decrease in HDL levels in 
diabetic rats was improved by BBR treatment indicating its 
beneficial effect on cardiovascular risk of diabetic animals. In 
particular, LDL-CH being involved in the transport of cholesterol 
from the liver to peripheral tissues is the key factor in atherogenesis 
[42]. The oxidative modification of LDL-CH is implicated in the 
atherosclerotic plaque in the blood vessels.  
The atherogenic index (AI), which indicates the deposition of fatty 
plaque in blood vessels is correlated to cardiovascular disease [43]. 
In the present study, a decrease in AI and CRI in BBR treated rats as 
compared to diabetic control rats indicated that BBR may decrease 
deposition of fatty plaque in blood vessels. Thus the significant 
reduction of AI and CRI demonstrates the potential of berberine 
treatment on reducing the risk of cardiovascular complications.  
Increased production of reactive oxygen species (ROS) and reduced 
cellular antioxidant mechanisms contribute to myocardial damage, 
apoptosis and then the remodelling. Moreover, it also leads to 
disturbances of myocardial energetics leading to loss of efficiency of 
myocardium. Since oxidative stress is a major factor contributing in 
the development of diabetic cardiomyopathy, the anti-oxidant 
mechanism of BBR may be one of the factors responsible for its 
protective effect against cardiomyopathy in diabetes mellitus. Type 
II diabetes mellitus induced by HFD-STZ resulted in classical 
metabolic disorder that exhibits not only hyperglycemia but also 
severe oxidative stress in the animals. This effect was evident from 
the reduced superoxide dismutase and catalase levels and increased 
MDA levels in the diabetic rats. It is apparent that BBR treatment 
increased the levels of catalase and superoxide dismutase while 
reduced the levels of MDA in diabetic rats indicating reduced lipid 
peroxidation. Antioxidant activity of BBR in type II diabetes mellitus 
presents a potential benefit over the conventional treatments that 
do not interfere with the disease progression process.  
Experimentally induced diabetes has been shown to cause an 
increase in the accumulation of protein and collagen formation. This 
causes structural and functional changes in the cardiac tissue, which 
causes myocardial fibrosis and stiffness resulting in cardiac 
dysfunction. Fibrous tissue formation and accumulation of collagen 
increases the left ventricular mass in diabetic rats [44]. Treatment 
with BBR could attenuate both cardiac and left ventricular 
hypertrophy indices significantly, thereby indicating its preventive 
effect on cardiac remodeling. 
In STZ-HFD diabetes, persistent hyperglycemia and other 
pathological factors like reactive oxygen species (ROS), glycation of 
proteins, lipids and vital molecules of the cell, inflammatory 
cytokines etc. cause substantial damage to the kidney. Such changes 
in diabetic kidney result in loss of nephrons and therefore increased 
formation of urine. In addition to this, glomerular basement 
membrane thickening, glomerulosclerosis and increase in mesangial 
matrix deposition also results in loss of renal function. Not only 
glucose toxicity but also the low-grade renal tissue inflammation 
leads to renal tubular damage as well as alteration of glomerular 
filtration barrier, loss of glomerular charge selectivity and loss of 
glomerular size selectivity [45]. Diabetic nephropathy progresses 
from microalbuminuria to macroalbuminuria leading to end-stage 
renal disease (ESRD). Microalbuminuria is also a strong predictor of 
cardiovascular disease in patients with diabetes [46].  
In the present study, we evaluated kidney function parameters, 
including blood urea nitrogen (BUN), serum creatinine, plasma urea 
and uric acid, to assess the effect of BBR on diabetic nephropathy. 
Treatment with BBR reduced the level of these parameters 
indicating a protective effect of BBR against inflammation of renal 
tissue and kidney damage. Proteinuria is considered to be the gold 
standard for screening and staging of diabetic renal damage. 
Diabetic control animals in our study developed prominent 
proteinuria. However, treatment with BBR reduced urinary protein 
indicating a protective effect of BBR against renal glomerular and 
tubular damage. This nephroprotective effect is further confirmed 
from the histopathological study of the kidney, which shows normal 
histology, reduction in cytoplasmic vacuolation of tubules, tubular 
dilation and lymphocytic infiltration. Moreover, in the present study, 
a decrease in the urine volume by BBR as compared to diabetic 
control indicates the possible role of BBR in the restoration of 
abnormalities in urine volume. 
Weight gain is an important characteristic of type II diabetes 
mellitus, which is due to the consumption of a diet rich in energy in 
the form of saturated fats (lard) and its deposition in various body 
fat pads. During the experimental period of 28 d, we noticed that the 
rat fed on a high-fat diet showed hyperphagia with an initial increase 
in body weight. Significant reduction in the body weight and basal 
metabolic index (BMI) during the treatment period with berberine 
as compared to disease control indicates homeostasis in 
carbohydrate and protein metabolism. 
Significant increase in feed intake and water intake in diabetic 
animals could be due to poor glycemic control. Reduction in feed 
intake and water intake after treatment with BBR might be a result 
of insulin-like action or improvement in peripheral glucose 
utilization. 
Bandawane et al. 




Conclusively, our study demonstrates that a combination of high-fat 
diet and streptozotocin injection effectively generated a rat model 
that mimics the natural history and metabolic characteristics of type 
II diabetes in humans. Observations from our study demonstrate 
that berberine effectively showed antidiabetic activity at dose-
dependent manner (75 mg/kg and 150 mg/kg) in diabetic animals. 
BBR also showed a beneficial effect on parameters of diabetic 
nephropathy and cardiomyopathy, indicating less cardiac and renal 
damage inflicted by diabetes mellitus. 
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